COVID-19 Mortality and Obstructive Airway Diseases

Patients hospitalized with COVID-19 who have comorbid asthma, chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO) have a significantly lower probability of survival than patients without these comorbidities, according to research presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2022 Annual Meeting, held in Phoenix, Arizona, February 25-28.


Continue reading

Seeking to determine the effects of obstructive airways diseases on COVID-19 outcomes, Korean researchers conducted a study of 5625 patients hospitalized with COVID-19, who were divided into groups of asthma, COPD, d COA and control. Patient data was analyzed to determine likelihood of survival as well as factors affecting COVID-19-related mortality, disease severity, and oxygen demand.

The researchers found that the mortality rates for patients in the asthma, COPD, and ACO groups were 2.3, 4.8, and 5.5 times higher, respectively, than for patients in the control group. The researchers further noted that patients in the asthma, COPD, and ACO groups were more likely to require oxygen and mechanical ventilation.

The researchers noted that “further studies are needed to assess the effect of chronic obstructive airway disease, particularly COA, on COVID-19 mortality.”

To visit Pneumology Advisor conference section for full coverage of the 2022 AAAAI Annual Meeting.

Reference

Shin E, Jin J, Park SY, et al. Impact of asthma, COPD and ACO on the prognosis of COVID-19. Presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI); February 25-28, 2022; Phoenix, AZ. Summary 177.

Comments are closed.